RPHM vs. VAXX, FIXX, IMRX, KZR, SCYX, GMTX, GANX, VHAQ, CKPT, and HCWB
Should you be buying Reneo Pharmaceuticals stock or one of its competitors? The main competitors of Reneo Pharmaceuticals include Vaxxinity (VAXX), Homology Medicines (FIXX), Immuneering (IMRX), Kezar Life Sciences (KZR), SCYNEXIS (SCYX), Gemini Therapeutics (GMTX), Gain Therapeutics (GANX), Viveon Health Acquisition (VHAQ), Checkpoint Therapeutics (CKPT), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
Vaxxinity (NASDAQ:VAXX) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Vaxxinity presently has a consensus target price of $7.00, suggesting a potential upside of 5,782.35%. Reneo Pharmaceuticals has a consensus target price of $18.14, suggesting a potential upside of 979.61%. Given Reneo Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Vaxxinity is more favorable than Reneo Pharmaceuticals.
Vaxxinity has higher revenue and earnings than Reneo Pharmaceuticals. Reneo Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
Reneo Pharmaceuticals received 15 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 58.82% of users gave Reneo Pharmaceuticals an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
In the previous week, Vaxxinity had 3 more articles in the media than Reneo Pharmaceuticals. MarketBeat recorded 4 mentions for Vaxxinity and 1 mentions for Reneo Pharmaceuticals. Vaxxinity's average media sentiment score of 1.73 beat Reneo Pharmaceuticals' score of -0.10 indicating that Reneo Pharmaceuticals is being referred to more favorably in the news media.
83.0% of Vaxxinity shares are held by institutional investors. Comparatively, 91.0% of Reneo Pharmaceuticals shares are held by institutional investors. 59.1% of Vaxxinity shares are held by insiders. Comparatively, 17.9% of Reneo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Vaxxinity's return on equity of -73.14% beat Reneo Pharmaceuticals' return on equity.
Vaxxinity has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, Reneo Pharmaceuticals has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.
Summary
Vaxxinity beats Reneo Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Reneo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPHM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reneo Pharmaceuticals Competitors List
Related Companies and Tools
